Yüklüyor......
Temozolomide does not impair gene therapy-mediated antitumor immunity in syngeneic brain tumor models
PURPOSE: Glioblastoma multiforme (GBM) is the most common primary brain cancer in adults. Chemotherapy with temozolomide (TMZ) significantly prolongs the survival of GBM patients. However, the 3-year survival is still ~5%. Herein we combined intratumoral administration of an adenoviral vector expres...
Kaydedildi:
| Asıl Yazarlar: | , , , , , , , , , |
|---|---|
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
2014
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3959570/ https://ncbi.nlm.nih.gov/pubmed/24501391 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-13-2140 |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|